臨床外科64巻7号

2009年07月発行

特集 肝胆膵癌に対する補助療法―治療成績の向上を目指して

肝胆膵癌に対する補助療法の現況

著者： 中津宏基¹ 岡正朗¹ 上野富雄¹ 吉村清¹ 為佐卓夫¹ 鈴木伸明¹ 坂本和彦¹ 飯田通久¹ 徳久善弘¹ 吉田晋¹

所属機関： ¹山口大学大学院医学系研究科消化器・腫瘍外科学

ページ範囲：P.879 - P.884

文献概要

要旨：肝胆膵癌に対する第一の根治的療法は外科的切除術であるが，進行癌として発見されることも多く，高い再発率と死亡率を呈している．根治術後のより有効な補助療法が必要であるが，この領域においては決定的なエビデンスが少なく，確立された補助療法がないのが現状である．しかし，進行癌に対する種々の抗癌剤，分子標的治療薬，免疫療法やその併用療法といった開発・臨床試験が進められており，術後補助療法においても膵癌のように大規模比較試験のエビデンスが集積されてきている．肝胆膵領域に比較的症例の多いわが国からその予後を改善させるべく質の高い臨床研究を進めていかねばならない．

参考文献

1）Hasegawa K, Takayama T, Ijichi M, et al：Uracil-tegafur as an adjuvant for hepatocellular carcinoma：a randomized trial. Hepatology 44：891-895, 2006

2）Li JQ, Zhang YQ, Zhang WZ, et al：Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 121：364-366, 1995

3）Lau WY, Leung TW, Ho SK, et al：Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma：a prospective randomised trial. Lancet 353：797-801, 1999

4）Lau WY, Lai EC, Leung TW, et al：Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma：a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247：43-48, 2008

5）Nagano H, Sakon M, Eguchi H, et al：Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 54：172-179, 2007

6）Llovet JM, Ricci S, Mazzaferro V, et al：Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359：378-390, 2008

7）Hui D, Qiang L, Jian W, et al：A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 41：36-41, 2009

8）Takayama T, Sekine T, Makuuchi M, et al：Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma：a randomised trial. Lancet 356：802-807, 2000

9）McMasters KM, Tuttle TM, Leach SD, et al：Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174：605-608, discussion 608-609, 1997

10）Jarnagin WR, Ruo L, Little SA, et al：Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma：implications for adjuvant therapeutic strategies. Cancer 98：1689-1700, 2003

11）Takada T, Amano H, Yasuda H, et al：Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95：1685-1695, 2002

12）伊賀芳朗，吉田奎介，杉本不二雄，他：胆道癌切除症例に対する5-FU，MMC，OK-432による術後補助免疫化学療法―新潟地区における共同研究によるProspective Randomized Trial．Biotherapy 4：1787-1793，1990

13）Kalser MH, Ellenberg SS：Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120：899-903, 1985

14）Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59：2006-2010, 1987

15）Klinkenbijl JH, Jeekel J, Sahmoud T, et al：Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region：phase Ⅲ trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230：776-782, discussion 782-784, 1999

16）Neoptolemos JP, Stocken DD, Friess H, et al：A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350：1200-1210, 2004

17）Burris HA, 3rd, Moore MJ, Andersen J, et al：Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer：a randomized trial. J Clin Oncol 15：2403-2413, 1997

18）Oettle H, Post S, Neuhaus P, et al：Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer：a randomized controlled trial. Jama 297：267-277, 2007

19）Maeda A, Boku N, Fukutomi A, et al：Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer：Japan Adjuvant Study Group of Pancreatic Cancer（JASPAC-01）. Jpn J Clin Oncol 38：227-229, 2008

20）Laheru D, Lutz E, Burke J, et al：Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer：a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14：1455-1463, 2008